History Highlight


10 Submission of Clinical trial Phase 3 application to MFDS
05 Completion of Clinical trial Phase 1/2
02 Initiation of Clinical trial Phase 2
01 Completion of Clinical trial Phase 1


12 Initiation of Clinical trial Phase 1
08 Approved for Authorization of Export by MFDS
07 Approved for GMP and Clinical trial Phase 1 by MFDS
06 Scheduled to inspection for GMP & Authorization for Export
04 Submission of Clinical trial application to MFDS
03 Completion of clinical trial production


11 Completion of pre-clinical study
10 Approved for drug manufacturing by MFDS
06 CPhI China 2019 - Exhibitor
04 Completion of Plant
02 Pre-clinical trial product & Start pro-clinical study(Feb. 15)
Issued new shares(44million)


12 Process development for Pre-clinical trial product
Issued new shares(19million)
11 Characterization of Botulinum Toxin
10 Contracted with Pre-Clinical Trial CRO (Biotoxtech.co.Ltd)


02 Animal experimental facilities registration
01 Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01)
Botulinum movement and retention report Korea Centers for Disease Control and Prevention (Management No.: 4-026-CBB-CO-040)


12 Extension of expansion of R&D Center (in Hyangnam-eup, Hwaseong-si, Gyeonggi-do)
08 Acquire license of medical device manufacturing (for export)
Acquire license of medical device manufacturing
07 Took over MEDICA Korea Co., Ltd. (USD 33million)
04 Established Seoul office (Diplomatic center)
Transferred PROTOX HQ. (Anseong GMP Factory)
03 Took over Anseong GMP factory (10,000m2) as subsidiary of DSK


12 Authorized venture company (Korea Technology Finance Corporation)
11 Established PROTOX CO., LTD.